Evidence map›Paper›PMID 34837562›Full record

ArticleApoptosis : an international journal on programmed cell death2022

Anti-neoplastic pharmacophore benzophenone-1 coumarin (BP-1C) targets JAK2 to induce apoptosis in lung cancer.

Ankith Sherapura, Vikas H Malojirao, Prabhu Thirusangu, B S Sharath, Shivananda Kandagalla, V Vigneshwaran, Jurica Novak, Lakshmi Ranganatha, Y L Ramachandra, Shrinath M Baliga and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Ankith SherapuraMolecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College, Kuvempu University, Shivamogga, Karnataka, 577203, India.
Vikas H MalojiraoMolecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College, Kuvempu University, Shivamogga, Karnataka, 577203, India.
Prabhu ThirusanguMolecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College, Kuvempu University, Shivamogga, Karnataka, 577203, India.
B S SharathSchool of System Biomedical Science and Department of Bioinformatics and Lifescience, Soongsil University, Seoul, South Korea.
Shivananda KandagallaLaboratory of Computational Modelling of Drugs, Higher Medical and Biological School, South Ural State University, Chaikovskogo 20A, Chelyabinsk, Russia, 454008.
V VigneshwaranMolecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College, Kuvempu University, Shivamogga, Karnataka, 577203, India.
Jurica NovakLaboratory of Computational Modelling of Drugs, Higher Medical and Biological School, South Ural State University, Chaikovskogo 20A, Chelyabinsk, Russia, 454008.
Lakshmi RanganathaDepartment of Chemistry, The National Institute of Engineering, Mysuru, Karnataka, 570008, India.
Y L RamachandraDepartment of Studies and Research in Biotechnology and Bioinformatics, Kuvempu University, Jnanasahyadri, Shankaraghatta, 577 451, India.
Shrinath M BaligaDepartment of Radiation Oncology, Mangalore Institute of Oncology, Mangalore, Karnataka, 575 002, India.
Shaukath Ara KhanumDepartment of Chemistry, Yuvaraja's College (Autonomous), University of Mysore, Mysuru, Karnataka, 570 005, India. shukathara@yahoo.co.in.
B T PrabhakarMolecular Biomedicine Laboratory, Postgraduate Department of Studies and Research in Biotechnology, Sahyadri Science College, Kuvempu University, Shivamogga, Karnataka, 577203, India. prabhakarbt@gmail.com.
Kuvempu University · INSouth Ural State University · RUMangalore Institute of Oncology · INSoongsil University · KRUniversity of Mysore · INWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reigning of the abnormal gene activation associated with survival signalling in lung cancer leads to the anomalous growth and therapeutic failure. Targeting specific cell survival signalling like JAK2/STAT3 nexus has become a major focus of investigation to establish a target specific treatment. The 2-bromobenzoyl-4-methylphenoxy-acetyl hydra acetyl Coumarin (BP-1C), is new anti-neoplastic agent with apoptosis inducing capacity. The current study was aimed to develop antitumor phramacophore, BP-1C as JAK2 specific inhibitor against lung neoplastic progression. The study validates and identifies the molecular targets of BP-1C induced cell death. Cell based screening against multiple cancer cell lines identified, lung adenocarcinoma as its specific target through promotion of apoptosis. The BP-1C is able to induce, specific hall marks of apoptosis and there by conferring anti-neoplastic activity. Validation of its molecular mechanism, identified, BP-1C specifically targets JAK2

Indexed as

ApoptosisLung NeoplasmsBenzophenonesCell Line, TumorCell ProliferationCoumarinsHumansJanus Kinase 2STAT3 Transcription FactorBenzophenonesCoumarinsJAK2 protein, humanJanus Kinase 2STAT3 Transcription FactorApoptosisBenzophenoneCoumarinJAK2/STAT3Lung cancer

Identifiers

PMID34837562
OpenAlexW3216434564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.